Potential predictors of immunotherapy in small cell lung cancer.
PD-L1 expression
molecular subtyping
mutational burden
small cell lung cancer
tumor microenvironment
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
01
2023
accepted:
18
04
2023
medline:
22
5
2023
pubmed:
19
5
2023
entrez:
19
5
2023
Statut:
epublish
Résumé
Lung cancer is one of the leading causes of cancer-related deaths worldwide, with small cell lung cancer (SCLC) having the worst prognosis. SCLC is diagnosed late in the disease's progression, limiting treatment options. The most common treatment for SCLC is chemotherapy. As the disease progresses, immunotherapy, most commonly checkpoint inhibitor medication, becomes more important. Efforts should be made in the development of immunotherapy to map specific biomarkers, which play a role in properly assigning a type of immunotherapy to the right cohort of patients, where the benefits outweigh any risks or adverse effects. The objective of this review was to provide a thorough assessment of current knowledge about the nature of the tumor process and treatment options for small cell lung cancer, with a focus on predictive biomarkers. According to the information obtained, the greatest potential, which has already been directly demonstrated in some studies, has characteristics such as tumor microenvironment composition, tumor mutation burden, and molecular subtyping of SCLC. Several other aspects appear to be promising, but more research, particularly prospective studies on a larger number of probands, is required. However, it is clear that this field of study will continue to expand, as developing a reliable method to predict immunotherapy response is a very appealing goal of current medicine and research in the field of targeted cancer therapy.
Identifiants
pubmed: 37206058
doi: 10.3389/pore.2023.1611086
pii: 1611086
pmc: PMC10191143
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1611086Informations de copyright
Copyright © 2023 Skopelidou, Strakoš, Škarda, Raška and Kafková-Rašková.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Thorac Oncol. 2019 May;14(5):914-923
pubmed: 30735815
Nat Rev Cancer. 2019 May;19(5):289-297
pubmed: 30926931
J Exp Clin Cancer Res. 2020 May 18;39(1):89
pubmed: 32423420
J Pers Med. 2021 Oct 27;11(11):
pubmed: 34834454
World J Gastroenterol. 2018 Aug 21;24(31):3500-3512
pubmed: 30131656
Radiographics. 2014 Oct;34(6):1707-21
pubmed: 25310425
Ann Oncol. 2021 Jul;32(7):839-853
pubmed: 33864941
Surg Oncol Clin N Am. 2016 Jul;25(3):447-68
pubmed: 27261908
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33393507
Front Oncol. 2021 Mar 11;11:617335
pubmed: 33777757
Eur J Cancer. 2020 May;131:40-50
pubmed: 32278982
Dtsch Arztebl Int. 2011 Aug;108(31-32):525-31
pubmed: 21886665
In Silico Biol. 2021;14(1-2):1-12
pubmed: 33216021
Cancer Cell. 2021 Mar 8;39(3):346-360.e7
pubmed: 33482121
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
J Clin Oncol. 2017 Dec 1;35(34):3823-3829
pubmed: 28813164
Ann Transl Med. 2018 Nov;6(Suppl 1):S48
pubmed: 30613623
Lancet Oncol. 2016 Dec;17(12):e542-e551
pubmed: 27924752
Klin Onkol. 2016 Fall;29 Suppl 4(Suppl 4):72-77
pubmed: 27846724
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Chest. 2013 Jan;143(1):146-151
pubmed: 22847040
J Clin Invest. 2013 Jul;123(7):2756-63
pubmed: 23863633
Vet Sci. 2015 Dec 01;2(4):423-439
pubmed: 29061951
J Clin Invest. 2007 May;117(5):1130-6
pubmed: 17476342
Oncologist. 2016 Aug;21(8):910-21
pubmed: 27354668
Int J Mol Sci. 2021 Oct 15;22(20):
pubmed: 34681779
Vnitr Lek. 2018 Winter;63(11):876-883
pubmed: 29303289
Anticancer Res. 2018 Apr;38(4):2155-2160
pubmed: 29599334
Science. 2018 Mar 23;359(6382):1366-1370
pubmed: 29567708
Ann Transl Med. 2021 May;9(9):809
pubmed: 34268422
Clin Chest Med. 2011 Dec;32(4):669-92
pubmed: 22054879
J Thorac Oncol. 2019 Jul;14(7):1286-1295
pubmed: 31078775
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Lung Cancer. 2019 Nov;137:31-37
pubmed: 31525648
Cancers (Basel). 2020 Sep 04;12(9):
pubmed: 32899891
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
J Thorac Oncol. 2013 May;8(5):587-98
pubmed: 23546044
Front Oncol. 2020 May 20;10:741
pubmed: 32509576
Cancer. 2010 Apr 1;116(7):1767-75
pubmed: 20143434
Mol Ther Oncolytics. 2021 Feb 06;20:470-483
pubmed: 33718595
Lancet. 2021 Aug 7;398(10299):535-554
pubmed: 34273294
Cancer Immunol Immunother. 2018 Nov;67(11):1659-1667
pubmed: 30232519
J Thorac Dis. 2018 Aug;10(8):4689-4693
pubmed: 30233840
Am Fam Physician. 2015 Feb 15;91(4):250-6
pubmed: 25955626
Lancet. 2011 Nov 12;378(9804):1741-55
pubmed: 21565397
J Thorac Oncol. 2016 Jun;11(6):789-800
pubmed: 26845192
Thorac Cancer. 2021 Oct;12(19):2523-2525
pubmed: 34467633
Immunology. 2007 May;121(1):1-14
pubmed: 17386080
Nat Rev Dis Primers. 2021 Jan 14;7(1):3
pubmed: 33446664
Oncology (Williston Park). 2014 Nov;28 Suppl 3:39-48
pubmed: 25384886
Cancer Growth Metastasis. 2014 Jun 02;7:9-18
pubmed: 24926201
Virchows Arch. 2021 Jan;478(1):31-44
pubmed: 33486574
Nat Rev Clin Oncol. 2020 May;17(5):300-312
pubmed: 32055013
Nat Rev Cancer. 2017 Dec;17(12):725-737
pubmed: 29077690
Klin Onkol. 2017 Winter;30(Supplementum3):10-21
pubmed: 29239188
Asian J Pharm Sci. 2019 Jan;14(1):16-29
pubmed: 32104435
Eur J Cancer. 2018 Sep;101:191-200
pubmed: 30077124
Expert Rev Anticancer Ther. 2019 Feb;19(2):151-167
pubmed: 30590971
Hepatobiliary Surg Nutr. 2018 Dec;7(6):479-480
pubmed: 30652093
Transl Lung Cancer Res. 2018 Feb;7(1):50-68
pubmed: 29535912
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
Klin Onkol. 2015;28 Suppl 4:4S56-63
pubmed: 26647890
J Immunother Cancer. 2019 Aug 5;7(1):205
pubmed: 31383005
J Clin Invest. 2007 May;117(5):1137-46
pubmed: 17476343
Cancer Treat Rev. 2019 Sep;79:101887
pubmed: 31491661
Int J Cancer. 2012 Sep 15;131(6):E928-37
pubmed: 22532287
Future Oncol. 2016 Apr;12(7):931-43
pubmed: 26882955
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394
Curr Treat Options Oncol. 2020 Jun 29;21(8):64
pubmed: 32601742
Semin Roentgenol. 2011 Jul;46(3):178-86
pubmed: 21726702
Clin Transl Immunology. 2020 Nov 22;9(11):e1215
pubmed: 33251010
J Thorac Oncol. 2020 Apr;15(4):520-540
pubmed: 32018053
Sci Transl Med. 2018 Sep 19;10(459):
pubmed: 30232229
J Thorac Oncol. 2022 Mar;17(3):362-387
pubmed: 34808341
Chin J Cancer Res. 2020 Feb;32(1):115-128
pubmed: 32194311
Clin Transl Oncol. 2019 Aug;21(8):961-976
pubmed: 30637710
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-10
pubmed: 33979194
Immunity. 2009 Jun 19;30(6):899-911
pubmed: 19464196
Clin Lung Cancer. 2017 Mar;18(2):132-140
pubmed: 27520630
Cancer Treat Res. 2016;170:25-46
pubmed: 27535388
Trends Immunol. 2019 May;40(5):415-430
pubmed: 30992189
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32900861